----
Current ValuationThe current P/E ratio is -5.79, within the reasonable range, cheaper than 66.54% of the time in the past 3 years, and the industry ranks 401/604, the industry Median -2.09.
-5.79xP/E
--Stock price
-5.79xP/E
Stock price--
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -5.79x
- Typical range
- -6.36x–-3.46x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
020406080
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
GILDUSGilead Sciences | -57.57x | 148.62% | $186.53B |
MRNAUSModerna | -27.08x | 15.53% | $85.33B |
CSLLYUSCSL Limited | -23.93x | -- | $61.70B |
NTRAUSNatera | -298.09x | 6.99% | $57.34B |
RVMDUSRevolution Medicines | -23.51x | 62.12% | $41.57B |
ROIVUSRoivant Sciences | -93.84x | 146.49% | $24.99B |
BNTXUSBioNTech SE | -12.32x | 19.07% | $24.08B |
INSMUSInsmed | -24.59x | 74.54% | $21.52B |
SMMTUSSummit Therapeutics | -15.96x | 20.52% | $13.67B |
BBIOUSBridgebio Pharma | -18.58x | 29.04% | $12.85B |
PCVXUSVaxcyte | -10.45x | 48.18% | $11.12B |
MDGLUSMadrigal Pharma | -33.20x | 51.06% | $10.79B |
IBRXUSImmunityBio | -10.81x | 151.32% | $10.73B |
TWSTUSTwist Bioscience | -73.12x | 28.71% | $10.00B |
KYMRUSKymera Therapeutics | -31.11x | 5.24% | $9.32B |
CYTKUSCytokinetics | -9.76x | 6.46% | $8.73B |
ARWRUSArrowHead Pharma | -26.81x | 36,308.30% | $8.58B |
ABVXUSAbivax SA | -16.30x | 22.49% | $7.58B |
SYREUSSpyre Therapeutics | -50.42x | 45.67% | $7.57B |
IONSUSIonis Pharma | -12.84x | 50.60% | $7.26B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
